Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.54 |
| ▸ | GABRP | O00591 | 2/20 | 0.52 |
| ▸ | GABRD | O14764 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.52 |
| ▸ | GABRE | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402758 | 0.82 | CHRNB2 (0.57) | CHRNB2CHRNA4CHRNB4KDM4AKDM4C | |
| SCHEMBL22446850 | 0.80 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15825625 | 0.79 | GABRP (0.46) | CHRNB2CHRNA4CHRNB4GABRPGABRD | |
| SCHEMBL26004047 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3DPP4 | |
| SCHEMBL11714076 | 0.78 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL23771190 | 0.78 | CHRNB2 (0.76) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1972700 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Propanol SCHEMBL14742011 | 0.78 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7141671 | 0.76 | GABRP (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL10906588 | 0.76 | GABRP (0.43) | CHRNB2CHRNA4CHRNB4GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106008244-B | A kind of synthetic method of 4 dimethylamino valeric acid | 厦门大学 | 2017-10-03 | — | — | CN | claimed |
| CN-107072946-A | Lipids and lipid compositions for delivery of active agents | 诺华股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| CN-106008244-A | Method for synthesizing 4-dimethylamino pentanoic acid | 厦门大学 | 2016-10-12 | — | — | CN | claimed |
| US-9278907-B2 | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2016-03-08 | — | — | US | claimed |
| EP-2491005-B1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS JSC (LV) | 2014-07-23 | — | — | EP | claimed |
| CN-102666476-B | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | GRINDEKS JOINT STOCK COMPANY | 2014-07-09 | — | — | CN | claimed |
| CN-103547562-A | 4- [ (haloalkyl) (dimethyl) ammonio ] butanoates and their use in the treatment of cardiovascular disease | JSC GRINDEKS | 2014-01-29 | — | — | CN | claimed |
| CN-102666476-A | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | GRINDEKS JSC | 2012-09-12 | — | — | CN | claimed |
| US-20120220656-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | JSC GRINDEKS (LV) | 2012-08-30 | — | — | US | claimed |
| EP-2491005-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | Grindeks, A Joint Stock Company (LV) | 2012-08-29 | — | — | EP | claimed |
| WO-2011048201-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-04-28 | — | — | WO | claimed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2025-01-30 | — | — | US | disclosed |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-10-29 | — | — | US | disclosed |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-06-06 | — | — | US | disclosed |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| CN-1784396-A | p38 inhibitors and methods of their use | ARRAY BIOPHARMA INC (US) | 2006-06-07 | — | — | CN | disclosed |
| CN-1753888-A | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| EP-1599471-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | Astrazeneca AB (SE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004078753-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | CHRNB2 3394/4885CHRNA4 3656/4885CHRNB4 3168/4885 |
| US-20240182895-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | CHRNB2 3329/4885CHRNA4 3066/4885CHRNB4 3204/4885 |
| US-20250034571-A1 | NON-LIPOSOMAL SYSTEMS FOR NUCLEIC ACID DELIVERY | SNRPE, NPC1L1, LIPA | CHRNB2 3329/4885CHRNA4 3066/4885CHRNB4 3204/4885 |
| US-20120220656-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, ABAT, BBOX1 | CHRNB2 1156/4885CHRNA4 475/4885CHRNB4 521/4885 |
| US-12129467-B2 | Non-liposomal systems for nucleic acid delivery | SNRPE, NPC1L1, LIPA | CHRNB2 3329/4885CHRNA4 3066/4885CHRNB4 3204/4885 |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | RPS7, CYP3A7, CYP2A7 | CHRNB2 4625/4885CHRNA4 3754/4885CHRNB4 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.